FJFang Jia

Fang Jia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fang Jia has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Can Hou

    Department of Cardiovascular Medicine, The First People's Hospital of Changzhou, The Third Affiliated Hospital of Soochow University, 213000, Changzhou, Jiangsu Province, China

    3 shared publications
  • De-Bing Tong

    Department of Cardiology, The Third Affiliated Hospital of Soochow University, Changzhou, China

    3 shared publications
  • Si-Fan Fei

    Department of Cardiovascular Medicine, China

    3 shared publications
  • Jiayi Xu

    Department of Cardiovascular Medicine, The First People’s Hospital of Changzhou, The Third Affiliated Hospital of Soochow University, 213000 Changzhou, Jiangsu, China

    2 shared publications
  • Min Zhou

    Department of Cardiovascular Medicine, The First People’s Hospital of Changzhou, The Third Affiliated Hospital of Soochow University, 213000 Changzhou, Jiangsu, China

    2 shared publications
  • Yu Mao

    Department of Cardiology, The Third Affiliated Hospital of Soochow University, Changzhou, China

    2 shared publications

Latest Publications

  • Open Access

    Novel SCN5A Variant in a Patient With Dilated Cardiomyopathy Complicated by Conduction Disorders and Recurrent Ventricular Arrhythmias

    by Shun-Yi Shi, Li-Shang Zhai, Jing Zhu, De-Bing Tong, Yu Mao, Jun-Yu Huo, Ling Yang, Fang Jia

  • Open Access

    Protective Effects of Red Yeast Rice and the Associated Preparations on Gut Microbiota Against Atherosclerosis

    by Fang Jia, Jiayi Xu, Min Zhou, Yu Mao

    Currently, atherosclerotic cardiovascular disease (ASCVD) is the primary cause of mortality globally. Meanwhile, accumulating evidence continues to implicate gut microbiota and the associated metabolites in the pathogenesis and progression of atherosclerosis. Red yeast rice (RYR), a traditional functional food, contains monacolin K as the primary bioactive component, which exerts statin-like lipid-lowering effects. Thus, RYR plays a protective role in regulating lipid metabolism and preventing ASCVD through multiple pathways, including improving endothelial dysfunction, attenuating oxidative stress, and inhibiting inflammatory responses. Therefore, this review summarizes current evidence regarding the regulatory effects of RYR and the associated preparations on hyperlipidemia and ASCVD. Furthermore, we highlight the protective role of RYR in the management of hyperlipidemia, with particular emphasis on the capacity of RYR to modulate the gut microbiota and the associated metabolites, thereby exerting anti-atherosclerotic effects. By elucidating the intricate interactions between RYR and the gut microbiota, this review provides novel insights into the therapeutic potential of RYR and reveals possible roles for the gut microbiota in ASCVD prevention.

  • Transcutaneous Auricular Vagus Nerve Stimulation Ameliorates Heart Failure with Preserved Ejection Fraction Through Regulating Macrophage Polarization Mediated by Alpha7nAChR

    by Jun-Yu Huo, Can Hou, Fang Jia, Cong Xue, Xiao-Long Li, Ling Yang, Wan-Ying Jiang, Xiaoying Zhang

    Purpose This study aimed to investigate the effects of transcutaneous auricular vagus nerve stimulation (ta-VNS) on heart failure with preserved ejection fraction (HFpEF) and explore the related mechanisms. Methods Sprague–Dawley rats were fed a high-fat diet and N[w]-nitro-L-arginine methyl ester to establish an HFpEF model. Ta-VNS was achieved by electrical stimulation of the auricular concha. Histology and echocardiography were used to identify changes in cardiac function and pathology. RNA sequencing was used to explore the underlying mechanism. RT‒PCR, WB, and immunofluorescence staining were used to determine the effects of ta-VNS on macrophage polarization. In vitro, RAW264.7 cells were induced into the M1 or M2 type. An α7nAChR agonist and an α7nAChR inhibitor were used to explore the effects of α7nAChR on macrophage polarization. Finally, an α7nAChR inhibitor was used to determine whether the therapeutic effects of ta-VNS are related to α7nAChR. Results In vivo, ta-VNS alleviated cardiac dysfunction and pathological remodeling in rats with HFpEF. RNA sequencing demonstrated that the protective effects of ta-VNS on HFpEF were related to macrophage-mediated inflammatory responses. Ta-VNS decreased the expression of M1-type macrophage markers but increased the expression of M2-type markers. In vitro studies revealed that the α7nAChR agonist decreased the polarization of macrophages toward the M1 type, whereas the α7nAChR inhibitor reduced the polarization toward the M2 type. Furthermore, the α7nAChR inhibitor abolished the protective effects of ta-VNS on macrophage polarization and myocardial remodeling in rats with HFpEF. Conclusion Ta-VNS ameliorated HFpEF-induced cardiac remodeling, which was associated with the modulation of macrophage polarization.


  • Open Access

    Association of Insomnia, Lipid Profile, and Lipid-Lowering Medications: A Narrative Review

    by Fang Jia, Shun-Yi Shi, Si-Fan Fei, Min Zhou, Jian-Jun Li

    Sleep is a fundamental phenomenon that helps maintain normal physiological processes. Conversely, sleep disorders, usually presented as insomnia, are a common public health problem that can lead to multiple pathophysiological changes in humans, including lipid metabolic abnormality. Interestingly, several previous studies have examined the potential relation of insomnia to metabolic syndrome and hyperlipidemia and found that insomnia was associated with elevated plasma cholesterol and triglyceride concentrations. This review summarizes evidence regarding the linkage between insomnia and lipid abnormalities. Moreover, the underlying physiologic mechanisms linking insomnia to lipid abnormalities are systemically discussed. Finally, issues with lipid-lowering drugs and the risk of insomnia are also presented. This knowledge can improve our understanding of the pathophysiological features of insomnia, which may help to prevent and treat insomnia-induced dyslipidemia clinically.


  • Open Access

    Screening of biomarkers for diagnosing chronic kidney disease and heart failure with preserved ejection fraction through bioinformatics analysis

    by Can Hou, Jiayi Xu, Min Zhou, Junyu Huo, Xiaofei Wang, Wanying Jiang, Tong Su, Hui Wang, Fang Jia


  • Open Access

    Effects of salidroside on atherosclerosis: potential contribution of gut microbiota

    by Si-Fan Fei, Can Hou, Fang Jia

    Graphical This review seeks to offer a comprehensive look at how salidroside impacts gut microbiota and its potential therapeutic role in treating atherosclerosis. (A) Salidroside has been shown to have a positive impact on atherosclerosis by promoting the growth of beneficial bacteria and decreasing the levels of harmful bacteria in the body. (B) Salidroside has been shown to enhance the integrity and function of the intestinal mucosal barrier through its ability to suppress NF-κB and p38 MAPK signaling pathways, modulate the NF-κB/MAPK/JAK-STAT3 signaling pathways and increase the expression of antimicrobial peptides HD-5 and HD-6. (C) Salidroside can reduce TMAO production through reducing the abundance of Firmicutes and Proteobacteria. (D) Salidroside can improve the expression of SCFAs, through increasing the abundance of some special bacteria. (E) Salidroside can reduce LPS-induced inflammation, which is associated with the inhibition of the ROS-mediated PI3K/AKT/mTOR signaling pathway, the downregulation of exosome miR-199a-5p, and the attenuation of the Notch-Hes signaling pathway. (F) Salidroside can inhibit NLRP3-associated gut-coronary axis, including TLR4/MyD88/NF-κB/NLRP3 signaling pathway, AMPK/NF-κB/NLRP3 signaling pathway, and P2X7/NF-κB/NLRP3 signaling pathway.


  • Open Access

    Necroptosis and immune infiltration in hypertrophic cardiomyopathy: novel insights from bioinformatics analyses

    by Can Hou, Sifan Fei, Fang Jia

    Background: Hypertrophic Cardiomyopathy (HCM), a widespread genetic heart disorder, is largely associated with sudden cardiac fatality. Necroptosis, an emerging type of programmed cell death, plays a fundamental role in several cardiovascular diseases.Aim: This research utilized bioinformatics analysis to investigate necroptosis's implication in HCM.Methods: The study retrieved RNA sequencing datasets GSE130036 and GSE141910 from the Gene Expression Omnibus (GEO) database. It detected necroptosis-linked differentially expressed genes (NRDEGs) by reviewing both the gene set for necroptosis and the differently expressed genes (DEGs). The enriched signaling pathway of HCM was assessed using GSEA, while common DEGs were studied through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. Concurrently, the Protein-Protein Interaction network (PPI) proved useful for identifying central genes. CIBERSORT facilitated evaluating the correlation between distinct immune cell-type prevalence and NRDEGs by analyzing immune infiltration patterns. Lastly, GSE141910 dataset validated the expression ranks of NRDEGs and immune-cell penetration.Results: The investigation disclosed significant enrichment and activation of the necroptosis pathway in HCM specimens. Seventeen diverse genes, including CYBB, BCL2, and JAK2 among others, were identified in the process. PPI network scrutiny classified nine of these genes as central genes. Results from GO and KEGG enrichment analyses showed substantial connections of these genes to pathways pertaining to the HIF-1 signaling track, necroptosis, and NOD-like receptor signaling process. Moreover, an imbalance in M2 macrophage cells in HCM samples was observed. Finally, CYBB, BCL2, and JAK2 emerged as vital genes and were validated using the GSE141910 dataset.Conclusion: These results indicate necroptosis as a probable underlying factor in HCM, with immune cell infiltration playing a part. Additionally, CYBB, BCL2, JAK2 could act as potential biomarkers for recognizing HCM. This information forms crucial insights into the basic mechanisms of HCM and could enhance its diagnosis and management.


  • Open Access

    Antiatherosclerotic Effect and Molecular Mechanism of Salidroside

    by Si-Fan Fei, De-Bing Tong, Fang Jia

    Atherosclerotic cardiovascular disease is currently the leading cause of death worldwide. Its pathophysiological basis includes endothelial dysfunction, macrophage activation, vascular smooth muscle cell (VSMC) proliferation, lipid metabolism, platelet aggregation, and changes in the gut microbiota. Salidroside has beneficial effects on atherosclerosis through multiple pathways. In this review, we present studies on the regulatory effect of salidroside on atherosclerosis. Furthermore, we report the protective effects of salidroside against atherosclerosis by ameliorating endothelial dysfunction, suppressing macrophage activation and polarization, inhibiting VSMC proliferation, adjusting lipid metabolism, attenuating platelet aggregation, and modulating the gut microbiota. This review provides further understanding of the molecular mechanism of salidroside and new ideas for atherosclerosis management.


  • Do Patients with Myocardial Infarction with Non-Obstructive Coronary Arteries Have Similar Prognosis Compared to Ones with MI-CAD?

    by Fang Jia, Si-Fan Fei, De-Bing Tong, Sheng Zhang, Jian-Jun Li

    Acute myocardial infarction (AMI) is a leading cause of morbidity and mortality worldwide and it is primarily caused by acute plaque disruption and coronary occlusion. Recent studies suggest that myocardial infarction with non-obstructive coronary arteries (MINOCA) also occurs but the underlying mechanisms have not been fully understood until recently. The evidence also suggests that the clinical outcomes of patients presenting with MINOCA are similar to AMI patients with obstructive coronary artery disease (MI-CAD), including all-cause mortality and major adverse cardiovascular events. The present narrative review considers the risk factors, pathological changes, and outcomes associated with MINOCA and compares them with MI-CAD.


    • 1 January 2019
      • Vol. 23  (1) , 289-296

    ILK participates in renal interstitial fibrosis by altering the phenotype of renal tubular epithelial cells via TGF-β1/smad pathway

    by M. Li, H. Zhou, J. Di, M. Yang, F. Jia

    OBJECTIVE: To explore the specific role of ILK (integrin-linked kinase) in regulating renal fibrosis and its underlying mechanism. MATERIALS AND METHODS: NRK-52E cells were induced by transforming growth factor-beta 1 (TGF-beta 1) for observing phenotype change. Renal tubular epithelial cell marker, fibrosis marker and expression level of ILK in NRK-52E cells were also detected. After overexpression of ILK, phenotype change of NRK-52E cells was observed. For in vivo experiments, we constructed UUO (unilateral ureteral obstruction) model in CD1 mice. Renal tubular epithelial cell marker, fibrosis marker and expression level of ILK in UUO mice were detected. The regulatory effect of ILK on renal fibrosis was detected after injection of ILK over expression plasmid. Western blot was performed to detect related genes in the TGF-beta 1/smad pathway. RESULTS: Accompanied by the TGF-beta 1-induced phenotype change in NRK-52E cells, both mRNA and protein levels of ILK were upregulated. Overexpression of ILK remarkably stimulated the phenotype change in NRK-52E cells. Similarly, ILK was highly expressed in UUO mice. Renal fibrosis was aggravated after injection of ILK overexpression plasmid in UUO mice. Western blot results showed that expressions of p-smad3 and smad3 were upregulated during the process of renal fibrosis. CONCLUSIONS: ILK is upregulated during the process of renal fibrosis. ILK participates in the development of renal fibrosis by altering phenotypes of renal tubular epithelial cells via a TGF-beta 1/smad pathway.